Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Definitions

• the present disclosure relates to use of lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form, for the treatment of Bipolar II Disorder.
• Substituted heterocycle fused gamma-carbolines such as lumateperone are known to be 5-HT 2A or 5-HT2A/D2 receptor ligands, which are useful in treating central nervous system disorders. These compounds antagonize the serotonin-2A (5-HT2A) receptor, and/or modulate dopamine receptor signaling at the level of key intra-cellular phosphoproteins. Such compounds are principally known to be useful for the treatment of positive and negative symptoms of schizophrenia. At dopamine D2 receptors, these compounds have dual properties and act as both post-synaptic antagonists and pre-synaptic partial agonists.
• the compounds also stimulate serotonin reuptake inhibition, providing antidepressant activity for the treatment of schizoaffective disorder, co- morbid depression, and/or as a stand-alone treatment for major depressive disorder.
• the 5-HT 2A or 5-HT2A/D2 receptor ligands as described are also useful for the treatment of bipolar disorder and other psychiatric and neurodegenerative disorders, particularly behavioral disturbances associated with dementia, autism and other CNS diseases. These features may be able to improve the quality of life of patients with schizophrenia and enhance social function to allow them to more fully integrate into their families and their workplace. These compounds display differential dose-dependent effects, selectively targeting the 5-HT 2A receptor at low doses, while progressively interacting with the D2 receptor at higher doses. As a result, at lower doses, they are useful in treating sleep, aggression and agitation. At a high-dose, they can treat acute exacerbated and residual schizophrenia, bipolar disorders, and mood disorders.
• Lumateperone which is 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-lH- pyrido[3',4': 4,5]pyrrolo[l,2,3-de]quinoxalin-8(7H)-yl)-l-(4-fluorophenyl)-l-butanone, having the formula:
• PCT/US08/03340 and U.S. Pat. No. 7,081,455 also disclose methods of making substituted heterocycle fused gamma- carbolines and uses of these gamma-carbolines as serotonin agonists and antagonists useful for the control and prevention of central nervous system disorders such as addictive behavior and sleep disorders.
• WO 2011/133224 and U.S. 8,993,572 each incorporated herein by reference, disclose prodrugs/metabolites of substituted heterocycle fused gamma-carbolines for improved formulation, e.g., extended/controlled release formulation.
• This application discloses that heterocycle fused gamma-carboline N-substituted with a 4-fluorophenyl(4-hydroxy)butyl moiety are shown to have high selectivity for the serotonin transporter (SERT) relative to the
• WO 2009/145900 and U.S. 8,598,119 teaches that selected substituted heterocycle fused gamma-carboline compounds have nanomolar affinity for the serotonin reuptake transporter (SERT) and so are selective serotonin reuptake inhibitors.
• SERT serotonin reuptake transporter
• bipolar disorder also known as manic-depressive illness
• manic-depressive illness is a brain disorder that causes unusual shifts in mood, energy, activity levels, and the ability to carry out day-to-day tasks.
• bipolar disorder There are four basic types of bipolar disorder; all of them involve clear changes in mood, energy, and activity levels. These moods range from periods of extremely“up,” elated, and energized behavior (known as manic episodes) to very sad,“down,” or hopeless periods (known as depressive episodes). Less severe manic periods are known as hypomanic episodes.
• Bipolar I Disorder- defined by manic episodes that last at least 7 days, or by manic
• depressive episodes occur as well, typically lasting at least 2 weeks.
• Episodes of depression with mixed features having depression and manic symptoms at the same time are also possible.
• Bipolar II Disorder defined by a pattern of depressive episodes and hypomanic episodes, but not the full-blown manic episodes described above.
• Cyclothymic Disorder also called cyclothymia
• hypomanic symptoms as well numerous periods of depressive symptoms lasting for at least 2 years (1 year in children and adolescents). However, the symptoms do not meet the diagnostic requirements for a hypomanic episode and a depressive episode.
• bipolar disorder remains unclear, and the disorder remains resistant to treatment.
• Pharmaceutical treatments include mood stabilizing drugs, such as lithium or anticonvulsants (e.g., carbamazepine, lamotrigine, and valproate).
• mood stabilizing drugs such as lithium or anticonvulsants (e.g., carbamazepine, lamotrigine, and valproate).
• Conventional antidepressants such as selective serotonin reuptake inhibitors (SSRIs) are not only less effective for treating bipolar depression than for major depressive disorder, but they may do harm, by triggering manic episodes and rapid cycling.
• SSRIs selective serotonin reuptake inhibitors
• Antipsychotic medications are generally effective for short-term treatment of bipolar manic episodes in Bipolar I Disorder, but they are generally ineffective in treating Bipolar II Disorder and in maintenance treatment during depressive episodes. Moreover, many
• antipsychotic medications exhibit significant side effects, such as extrapy rami dal symptoms including acute dyskinesias and dystonic reactions, tardive dyskinesia, Parkinsonism, akinesia, akathisia, and neuroleptic malignant syndrome.
• Bipolar II Disorder is often misdiagnosed as either Major Depressive Disorder or Bipolar I Disorder, and improperly treated as a result.
• Bipolar II Disorder is often misdiagnosed as either Major Depressive Disorder or Bipolar I Disorder, and improperly treated as a result.
• lumateperone is useful to treat Bipolar II Disorder.
• Clinical results suggest that lumateperone is at least as effective in this indication as existing antipsychotic agents in treating bipolar disorders, with particularly unexpected efficacy in Bipolar II Disorder, which is often resistant to treatment with antipsychotic agents.
• lumateperone exhibits a favorable safety profile.
• the clinical trials demonstrate that, unlike many other antipsychotic agents, lumateperone does not increase akathisia, restlessness, or other movement disorders, it does not increase suicidal ideation, and it does not have significant metabolic side effects.
• the present disclosure provides a method for treating Bipolar II Disorder in a patient in need thereof, comprising administering a therapeutically effective amount of lumateperone, in free base or pharmaceutically acceptable salt form, optionally in deuterated form, to a patient in need thereof.
• MDRS Montgomery-Asberg Depression Rating Scale
• CGI-BP-S Clinical Global Impression Scale for Bipolar for Severity of Illness
• the patients did not exhibit emergence of mania as measured by the Young Mania Rating Scale (YMRS) and a specific clinical global impression of severity for mania, meaning that the drug was effective in preventing the emergence of mania or hypomania, and did not trigger manic episodes or cause rapid cycling that is often linked to SSRIs in treatment of bipolar disorders.
• YMRS Young Mania Rating Scale
• Lumateperone demonstrated a favorable safety profile in this trial, comparable to placebo. Unlike quetiapine, lumateperone did not appear to have any noticeable metabolic effects, such as such as hyperglycemia, dyslipidemia, or weight gain. There were no adverse event reports of suicidal ideation, no suicides, and no discontinuations due to suicidal thoughts. Equally important, there were also no adverse event reports of extrapy rami dal symptoms, such as akathisia, restlessness, or other motor side effects.
• the present disclosure provides a method (Method 1) for the treatment of Bipolar II Disorder, comprising administering to a patient in need thereof, a therapeutically effective amount of lumateperone, in free base or pharmaceutically acceptable salt form, optionally in deuterated form.
• Method 1 for the treatment of Bipolar II Disorder, comprising administering to a patient in need thereof, a therapeutically effective amount of lumateperone, in free base or pharmaceutically acceptable salt form, optionally in deuterated form.
• Method 1 wherein the lumateperone is in the form of the tosylate salt (e.g., an acid addition salt of toluenesulfonic acid, such as a mono-tosylate salt or bis-tosylate salt), optionally wherein the salt is a solid crystalline salt, such as those disclosed in US 2011/112105 and/or US 2020/0157100, the contents of each of which are incorporated by reference herein in their entireties.
• the tosylate salt e.g., an acid addition salt of toluenesulfonic acid, such as a mono-tosylate salt or bis-tosylate salt
• the salt is a solid crystalline salt, such as those disclosed in US 2011/112105 and/or US 2020/0157100, the contents of each of which are incorporated by reference herein in their entireties.
• the lumateperone is in deuterated form, e.g., wherein the deuterium: protium ratio for a specified carbon-bound hydrogen atom is significantly higher, e.g., at least 2x, for example at least lOx higher, than the natural isotope ratios.
• D represents a hydrogen position with substantially greater than natural deuterium incorporation (i.e., substantially greater than 0.0156%), e.g., greater than 60%, or greater than 70%, or greater than 80%, or greater than 90% or greater than 95%, or greater than 96%, or greater than 97%, or greater than 98%, or greater than 99%, in free or pharmaceutically acceptable salt form, e.g. tosylate salt form.
• any foregoing method wherein the lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form, is administered in a total daily dose equivalent to 6 to 60 mg of free base, e.g., equivalent to 20-50 mg of free base.
• any foregoing method wherein the lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form, is administered in a total daily dose equivalent to 25-30 mg of free base.
• any foregoing method wherein the lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form, is administered in a total daily dose equivalent to 40-45mg of free base.
• the method comprises once daily administration of a unit dosage for oral administration, for example a tablet or capsule, comprising about 42 mg of lumateperone free base equivalent, in free or pharmaceutically acceptable salt form, optionally in deuterated form, in combination or association with a pharmaceutically acceptable diluent or carrier.
• the method comprises once daily administration of a tablet or capsule comprising about 60 mg of lumateperone tosylate optionally in deuterated form, in combination or association with a pharmaceutically acceptable diluent or carrier.
• any foregoing method wherein the method comprises once daily administration of a unit dosage for oral administration, for example a tablet or capsule, comprising about 28 mg of lumateperone free base equivalent, in free or pharmaceutically acceptable salt form, optionally in deuterated form, in combination or association with a pharmaceutically acceptable diluent or carrier.
• any foregoing method wherein the method comprises once daily administration of a tablet or capsule comprising about 40 mg of lumateperone tosylate optionally in deuterated form, in combination or association with a pharmaceutically acceptable diluent or carrier.
• the method comprises once daily administration of a unit dosage for subcutaneous or transmucosal administration, e.g., a sublingual or buccal orally disintegrating tablet or film, comprising lumateperone in free or pharmaceutically acceptable salt form, optionally in deuterated form, in an amount equivalent to 10-60 mg of free base, and a pharmaceutically acceptable diluent or carrier.
• any foregoing method wherein the method comprises administration of lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form, in a long acting injectable form.
• Any foregoing method wherein the condition to be treated is depression in Bipolar II Disorder, or a depressive episode associated with Bipolar II Disorder (e.g., a major depressive episode).
• any foregoing method wherein the condition to be treated includes mixed affective episodes in Bipolar II Disorder.
• any foregoing method wherein the condition to be treated includes hypomanic episodes.
• MADRS Montgomery-Asberg Depression Rating Scale
• HAM-D Hamilton Depression Rating Scale
• BDI Beck Depression Inventory
• Zung Self-Rating Depression Scale the Wechsler Depression Rating Scale
• Raskin Depression Rating Scale the Inventory of Depressive Symptomatology (IDS)
• IDS Inventory of Depressive Symptomatology
• QIDS Quick Inventory of Depressive Symptomatology
• any foregoing method wherein, during the course of treatment, the patient shows improvement in the Montgomery-Asberg Depression Rating Scale (MADRS) total score (e.g., improvement within 8 days or less after initiation of treatment).
• MADRS Montgomery-Asberg Depression Rating Scale
• CGI-BP-S Clinical Global Impression Scale for Bipolar for Severity of Illness
• CGI-BP- Depression-S Clinical Global Impression Scale for Bipolar Depression for Severity of Illness
• CGI-S Clinical Global Impression - Severity
• CGI-I Clinical Global Impression- Improvement
• any foregoing method wherein the treatment does not induce extrapy rami dal symptoms e.g., one or more of akathisia, akinesia, restlessness, acute dyskinesia, dystonic reactions, tardive dyskinesia, Parkinson’ s-like symptoms, or neuroleptic malignant syndrome.
• any foregoing method wherein the lumateperone in free base or pharmaceutically acceptable salt form, optionally in deuterated form, is administered as monotherapy for treatment of Bipolar II Disorder.
• a mood-stabilizing agent e.g., selected from lithium, carbamazepine, oxcarbazepine, lamotrigine, and valproate (including divalproex (a.k.a. valproate semi sodium), sodium valproate, and other free, salt or complexed forms of valproic acid).
• a mood-stabilizing agent e.g., selected from lithium, carbamazepine, oxcarbazepine, lamotrigine, and valproate (including divalproex (a.k.a. valproate semi sodium), sodium valproate, and other free, salt or complexed forms of valproic acid).
• any foregoing method wherein the patient is an adult, e.g., over the age of 18, e.g., between the ages of 18 and 75, inclusive.
• Method 1.41 wherein said SSRI is selected from citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline.
• Method 1.43 wherein said antipsychotic is selected from haloperidol, aripiprazole, quetiapine, olanzapine, risperidone, lurasidone, paliperidone, iloperidone, ziprasidone, brexipiprazole, asenapine, clozapine, and zotepine.
• said antipsychotic is selected from haloperidol, aripiprazole, quetiapine, olanzapine, risperidone, lurasidone, paliperidone, iloperidone, ziprasidone, brexipiprazole, asenapine, clozapine, and zotepine.
• the disclosure provides lumateperone, in free or
• the disclosure provides the use of lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form, in the manufacture of a medicament for the treatment of Bipolar II Disorder, e.g., for use in any of Methods 1, et seq.
• treatment and “treating” are to be understood accordingly as embracing prophylaxis and treatment or amelioration of symptoms of disease and/or treatment of the cause of the disease.
• the words“treatment” and“treating” refer to prophylaxis or amelioration of symptoms of the disease.
• “Patient” as used herein means a human patient, unless otherwise indicated.
• Pharmaceutically acceptable salts of lumateperone include pharmaceutically acceptable acid addition salts, for example, toluenesulfonic acid addition salts (tosylate salts).
• Tosylate salts of lumateperone include the monotosylate salt and the bis-tosylate salt.
• the term“lumateperone tosylate” refers to the mono-tosylate salt.
• Lumateperone tosylate is sold as CaplytaTM. Where dosages or amounts of a salt are given by weight, e.g., milligrams per day or milligrams per unit dose, the dosage amount of the salt is given as the weight of the corresponding free base, unless otherwise indicated.
• the term“concurrently” when referring to a therapeutic use refers to administration of two or more active ingredients to a patient as part of a regimen for the treatment of a disease or disorder, whether the two or more active agents are given at the same or different times or whether given by the same or different routes of administrations. Concurrent administration of the two or more active ingredients may be at different times on the same day, or on different dates or at different frequencies.
• Lumateperone in free or pharmaceutically acceptable salt form, optionally in deuterated form, may be administered by any suitable route, including oral, parenteral, transdermal, or transmucosal, for example in the form of a tablet, a capsule, a subcutaneous injection, long acting injectable (depot), or an oral, rapidly disintegrating tablet or film for sublingual or buccal administration.
• lumateperone is provided as a tablet or capsule for oral administration, comprising lumateperone tosylate in combination with a pharmaceutically acceptable diluent or carrier.
• lumateperone is provided as a rapidly disintegrating tablet or film for sublingual or buccal administration, comprising lumateperone tosylate in combination with a pharmaceutically acceptable diluent or carrier.
• lumateperone in free or pharmaceutically acceptable salt form, optionally in deuterated form, is administered as a depot formulation, e.g., by dispersing, dissolving, suspending, or encapsulating the compound in a polymeric matrix as described in herein, such that the compound is continually released as the polymer degrades over time.
• the release of the lumateperone from the polymeric matrix provides for the controlled- and/or delayed- and/or sustained-release, e.g., from the pharmaceutical depot composition, into a subject, for example a warm-blooded animal such as man, to which the pharmaceutical depot is administered.
• the pharmaceutical depot delivers lumateperone to the subject at
• Depot composition of the Invention may include a polyester of a hydroxyfatty acid and derivatives thereof or other agents such as polylactic acid, polyglycolic acid, polycitric acid, polymalic acid, poly-beta. -hydroxybutyric acid, epsilon. -capro-lactone ring opening polymer, lactic acid-glycolic acid copolymer, 2-hydroxybutyric acid-glycolic acid copolymer, polylactic acid-polyethylene glycol copolymer or polyglycolic acid-polyethylene glycol copolymer), a polymer of an alkyl alpha-cyanoacrylate (for example poly(butyl 2-cyanoacrylate)), a
• polyalkylene oxalate for example polytrimethylene oxalate or polytetramethylene oxalate
• a polyortho ester for example polyethylene carbonate or polyethylene propylene carbonate
• a polycarbonate for example polyethylene carbonate or polyethylene propylene carbonate
• a poly ortho-carbonate for example poly-gamma. -L-alanine, poly- .gamma.-benzyl-L-glutamic acid or poly-y-methyl-L-glutamic acid
• a hyaluronic acid ester and the like, and one or more of these polymers can be used.
• the polymers are copolymers, they may be any of random, block and/or graft copolymers.
• any one of D-isomers, L- isomers and/or DL-isomers may be used.
• alpha-hydroxycarboxylic acid polymer preferably lactic acid-glycolic acid polymer
• its ester preferably lactic acid-glycolic acid polymer
• poly-alpha-cyanoacrylic acid esters etc.
• lactic acid-glycolic acid copolymer also referred to as poly(lactide-alpha- glycolide) or poly(lactic-co-glycolic acid), and hereinafter referred to as PLGA
• PLGA lactic acid-glycolic acid copolymer
• the polymer useful for the polymeric matrix is PLGA.
• the term PLGA includes polymers of lactic acid (also referred to as polylactide, poly(lactic acid), or PLA).
• the polymer is the biodegradable poly(d,l-lactide-co-glycolide) polymer, such as PLGA 50:50, PLGA 85: 15 and PLGA 90: 10
• the polymeric matrix of the invention is a biocompatible and biodegradable polymeric material.
• biocompatible is defined as a polymeric material that is not toxic, is not carcinogenic, and does not significantly induce inflammation in body tissues.
• the matrix material should be biodegradable wherein the polymeric material should degrade by bodily processes to products readily disposable by the body and should not accumulate in the body.
• the products of the biodegradation should also be biocompatible with the body in that the polymeric matrix is biocompatible with the body.
• polymeric matrix materials include poly(glycolic acid), poly-D,L-lactic acid, poly-L-lactic acid, copolymers of the foregoing, poly(aliphatic carboxylic acids), copolyoxalates, polycaprolactone, polydioxanone, poly(ortho carbonates), poly (acetals), poly(lactic acid- caprolactone), polyorthoesters, poly(glycolic acid-caprolactone), polyanhydrides, and natural polymers including albumin, casein, and waxes, such as, glycerol mono- and distearate, and the like.
• One suitable polymer for use in the practice of this invention is dl(polylactide-co-glycolide).
• the molar ratio of lactide to glycolide in such a copolymer be in the range of from about 75:25 to 50:50.
• Useful PLGA polymers may have a weight-average molecular weight of from about 5,000 to 500,000 Daltons, preferably about 150,000 Daltons. Dependent on the rate of degradation to be achieved, different molecular weight of polymers may be used. For a diffusional mechanism of drug release, the polymer should remain intact until all of the drug is released from the polymeric matrix and then degrade. The drug can also be released from the polymeric matrix as the polymeric excipient bioerodes.
• the PLGA may be prepared by any conventional method, or may be commercially available.
• PLGA can be produced by ring-opening polymerization with a suitable catalyst from cyclic lactide, glycolide, etc. (see EP-0058481B2; Effects of polymerization variables on PLGA properties: molecular weight, composition and chain structure).
• PLGA is biodegradable by means of the degradation of the entire solid polymer composition, due to the break-down of hydrolysable and enzymatically cleavable ester linkages under biological conditions (for example in the presence of water and biological enzymes found in tissues of warm-blooded animals such as humans) to form lactic acid and glycolic acid.
• Both lactic acid and glycolic acid are water-soluble, non-toxic products of normal metabolism, which may further biodegrade to form carbon dioxide and water.
• PLGA is believed to degrade by means of hydrolysis of its ester groups in the presence of water, for example in the body of a warm-blooded animal such as man, to produce lactic acid and glycolic acid and create the acidic microclimate. Lactic and glycolic acid are by-products of various metabolic pathways in the body of a warm-blooded animal such as man under normal physiological conditions and therefore are well tolerated and produce minimal systemic toxicity.
• any disclosure of a numerical range, e.g.,“up to X” amount is intended to include the upper numerical limit X. Therefore, a disclosure of“up to 60 mg” is intended to include 60 mg.
• All references cited herein are hereby incorporated by referenced in their entireties. In the event of a conflict in a definition in the present disclosure and that of a cited reference, the present disclosure controls.
• a multi-center, multi-national, randomized, double-blind, fixed-dose, placebo-controlled clinical trial is conducted substantially in accordance with the following protocol.
• a total of 381 patients recruited in accordance with the above criteria are randomized 1 : 1 to two study arms: (i) lumateperone 42 mg (administered orally as 60 mg of lumateperone tosylate) and (ii) placebo.
• lumateperone administered once daily every evening for 6 weeks.
• placebo is administered once daily every evening for 6 weeks.
• the total study duration is about 10 weeks, including up to 2 weeks screening period (washout of prohibited medications), a 6-week double-blind treatment period, and 2-week safety follow-up period.
• the primary outcome measure is the Montgomery -Asberg Depression Rating Scale (MADRS) [Time Frame: Day 43] Secondary outcome measures are the Clinical Global Impression Scale, Bipolar version (CGI-BP) [Time Frame: Day 43] and the Quality of Life Achievement and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) [Time Frame: Day 43] [0047]
• a further objective of the study is to determine the safety and tolerability of lumateperone versus placebo as measured by:
• AEs Incidence of Adverse Events
• YMRS Young Mania Rating Scale
• C-SSRS Columbia Suicide Severity Rating Scale
• AIMS Abnormal Involuntary Movement Scale
• SAS Simpson Angus Scale
• ECGs Electrocardiograms
• the patient disposition is as follows:
• Lumateperone 42 mg was thus superior to placebo as demonstrated by statistically significant improvements on MADRS Total Score and CGI-BP-S which were the primary and key secondary measures in this study. The improvements seen in this study with Lumateperone 42 mg are considered to be clinically meaningful.
• TEAEs treatment- emergent adverse events
• Lumateperone 42 mg was generally safe and well tolerated. The most commonly reportec adverse events that were observed at a rate greater than 5% and higher than placebo were headache, somnolence and nausea. Importantly, the rates of akathisia and extrapy rami dal symptoms were less than 1% and similar to placebo.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Psychiatry (AREA)
• Nutrition Science (AREA)
• Physiology (AREA)
• Inorganic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicinal Preparation (AREA)

Priority Applications (13)

Applications Claiming Priority (2)

Publications (1)

Family

ID=74066254

Family Applications (1)

Country Status (11)

Families Citing this family (15)

Citations (12)

Family Cites Families (108)

• 2020
  • 2020-07-07 WO PCT/US2020/041063 patent/WO2021007245A1/en not_active Ceased
  • 2020-07-07 CA CA3141223A patent/CA3141223A1/en active Pending
  • 2020-07-07 EP EP20837066.8A patent/EP3993798A4/en active Pending
  • 2020-07-07 MX MX2022000143A patent/MX2022000143A/es unknown
  • 2020-07-07 US US16/922,893 patent/US20210000822A1/en not_active Abandoned
  • 2020-07-07 KR KR1020227003969A patent/KR20220029744A/ko active Pending
  • 2020-07-07 CN CN202080049820.3A patent/CN114072150A/zh active Pending
  • 2020-07-07 AU AU2020311894A patent/AU2020311894B2/en active Active
  • 2020-07-07 BR BR112022000231A patent/BR112022000231A2/pt unknown
  • 2020-07-07 EP EP22191949.1A patent/EP4134101A1/en active Pending
  • 2020-07-07 JP JP2022500683A patent/JP7673040B2/ja active Active
• 2022
  • 2022-01-03 IL IL289589A patent/IL289589A/en unknown
  • 2022-01-03 MX MX2025005489A patent/MX2025005489A/es unknown
• 2023
  • 2023-10-25 US US18/494,754 patent/US12090155B2/en active Active
• 2024
  • 2024-07-19 US US18/777,765 patent/US20240374586A1/en active Pending
• 2025
  • 2025-04-23 JP JP2025071306A patent/JP2025121928A/ja active Pending
  • 2025-09-18 AU AU2025234205A patent/AU2025234205A1/en active Pending

Patent Citations (24)

Non-Patent Citations (6)

Also Published As

Similar Documents

Legal Events